Donepezil Transdermal Matrix with Styrene Copolymer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal drug delivery systems for donepezil suffer from low skin penetration rates, gastrointestinal side effects, and skin irritation, which reduce patient compliance and effectiveness in treating Alzheimer's dementia.
Innovation Solution
A transdermal drug delivery system comprising a matrix layer with donepezil, a styrene copolymer, hydrogenated rosin glycerol ester, and optionally a hydrocarbon resin, which enhances skin penetration, prevents crystallization, and minimizes skin irritation, maintaining therapeutic concentrations for at least 24 hours.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If the transdermal delivery system uses a large surface area to overcome low skin penetration rate, then skin penetration of donepezil is improved, but patient compliance decreases due to the large size
Solution Approach 1:
The patent changes the chemical composition parameters of the matrix system by using a eutectic mixture of donepezil with specific co-solvents (glycerol, propylene glycol, ethylene glycol) in optimized ratios. This parameter change enables high skin penetration at lower donepezil concentrations (2-10%), avoiding the need for large surface area patches while maintaining therapeutic effectiveness and patient compliance.
2Quantity of substance
If the drug concentration in the matrix is increased to more than 8% to improve therapeutic effect, then donepezil efficacy is improved, but crystalline solid forms which decrease adhesive force and create storage problems
Solution Approach 1:
The patent changes the physical state parameters of donepezil by forming a eutectic mixture with co-solvents. This parameter change allows the drug to remain in a stable, non-crystalline state at concentrations above 8%, preventing crystallization while maintaining high therapeutic potency and proper adhesive properties.
Solution Approach 2:
The patent creates a composite matrix system combining donepezil with specific co-solvents (glycerol, propylene glycol, ethylene glycol) in optimized ratios. This composite material approach prevents crystallization of pure donepezil while maintaining high drug concentration and therapeutic effectiveness.
3Ease of operation
If oral formulations of donepezil are used to treat Alzheimer's dementia, then ease of administration is improved, but gastrointestinal side effects and hepatic first-pass effect increase
Solution Approach 1:
The patent replaces the oral administration route with transdermal delivery. This substitution eliminates the gastrointestinal tract and liver first-pass metabolism from the drug delivery pathway, thereby eliminating gastrointestinal side effects and hepatic first-pass effect while maintaining ease of administration through simple patch application.
4Force
If acrylic pressure-sensitive adhesive is used as matrix to improve adhesion, then adhesive force is improved, but drug diffusion is slowed due to interaction between donepezil and acrylic polymer
Solution Approach 1:
The patent replaces acrylic pressure-sensitive adhesive with a eutectic mixture composite system comprising donepezil and specific co-solvents (glycerol, propylene glycol, ethylene glycol). This composite material provides both adequate adhesion and enhanced drug diffusion by preventing donepezil-polymer interactions that slow diffusion, while maintaining therapeutic drug delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves high and continuous skin penetration of donepezil, reduces crystallization, and minimizes skin irritation, improving patient compliance and treatment effectiveness.
Implementation Method 1
the drug diffusion is slowed in the pressure-sensitive adhesive layer due to the interaction between donepezil and the acrylic polymer in the layer, which also reduce movement of the drug from the pressure-sensitive adhesive layer to the skin
Implementation Method 2
a specific crystallization-inhibiting agent (a methacrylate copolymer having a carboxyl group)
Data Source
AI summary
Certain embodiments of the invention relates to a transdermal drug delivery system containing donepezil or a pharmaceutically acceptable salt thereof as an active ingredient, more specifically to a transdermal drug delivery system containing a drug-containing matrix layer comprising donepezil or its pharmaceutically acceptable salt, a styrene copolymer, a hydrogenated rosin glycerol ester, and optionally a hydrocarbon resin.